Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Aptamer Bioconjugates for Cancer Therapy

  • Omid C. Farokhzad
  • Robert Langer
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_375-2


Over the past two decades, a large body of data has been generated that demonstrates the feasibility of antibodies for tissue targeting. The first FDA approval of a humanized monoclonal antibody for the treatment of cancer came in 1997 when rituximab (Rituxan) entered the market for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma. A wide variety of ligand-drug conjugates are now under clinical development or in clinical practice today. For example, gemtuzumab (Mylotarg) is an FDA-approved chemoimmunoconjugate for the treatment of acute myelogenous leukemia. Mylotarg is one of the four FDA-approved therapeutic conjugates. There are many others that are currently in various stages of clinical and preclinical development. In addition to antibodies, there is a growing list of ligand classes underdevelopment that are capable of binding to target antigens with high affinity and specificity. One...


Drug Delivery Vehicle Nuclease Degradation Tertiary Conformation Clinical Practice Today Nucleic Acid Therapeutics 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822CrossRefPubMedGoogle Scholar
  2. Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58:1456–1459CrossRefPubMedGoogle Scholar
  3. Farokhzad OC, Jon S, Khademhosseini A et al (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64:7668–7672CrossRefPubMedGoogle Scholar
  4. Farokhzad OC, Cheng J, Teply BA et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103:6315–6320CrossRefPubMedPubMedCentralGoogle Scholar
  5. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Laboratory of Nanomedicine and Biomaterials, Department of AnesthesiologyBrigham and Women’s HospitalBostonUSA
  2. 2.Department of Chemical Engineering and Center for Cancer ResearchMassachusetts Institute of TechnologyCambridgeUSA